Natural products as Anti-glycation agents: Possible therapeutic potential for diabetic complications

Current Diabetes Reviews

Volumn 8, Issue 2, 2012, Pages 92-108

  Elosta, Abdulhakim ^a   Ghous, Tahseen ^a   Ahmed, Nessar ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Advanced glycation endproducts; Antioxidants; Curcumin; Diabetes mellitus; Garlic; Luobuma; Maillard; Natural products

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; ANTIOXIDANT; CHELATING AGENT; CURCUMIN; DEFEROXAMINE; ENDOTHELIN 1; GLYOXAL; IBUPROFEN; MESSENGER RNA; METHYLGLYOXAL; NATURAL PRODUCT; OXYGEN RADICAL; PARACETAMOL; PLANT EXTRACT; SCHIFF BASE; THIAMINE; TOBACCO SMOKE; TRANSITION ELEMENT; TURMERIC; VASCULAR CELL ADHESION MOLECULE 1;

AMADORI REARRANGEMENT; ARTERIAL STIFFNESS; AUTOOXIDATION; BARK; BLOOD GLUCOSE MONITORING; BUCKWHEAT; CATARACT; CATARACTOGENESIS; CELLULAR DISTRIBUTION; CHEMICAL BINDING; CHEMICAL INTERACTION; CINNAMON; CLOVE; CORNUS; CYPERUS ROTUNDUS; DECOMPOSITION; DEFENSE MECHANISM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG ACTIVITY; ELEUTHEROCOCCUS SENTICOSUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; FOOD; FRUIT; GARLIC; GOOSEBERRY; GROWTH INHIBITION; GUAVA; HEVEA BRASILIENSIS; HUMAN; HYPERGLYCEMIA; LAURUS NOBILIS; LIGAND BINDING; MEDICINAL PLANT; MOLECULAR WEIGHT; MOMORDICA CHARANTIA; MORBIDITY; MORTALITY; MUNG BEAN; NONHUMAN; NUCLEOPHILICITY; NUTMEG; ONION; OXIDATION; PAEONIA LACTIFLORA; PASSION FRUIT; PEAR; PLANT LEAF; PLANT ROOT; POMEGRANATE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; REVIEW; RICE; RISK ASSESSMENT; ROSEMARY; SUPPLEMENTATION; TEA; THUJA; THYME; TOMATO; UPREGULATION;

ANTIOXIDANTS; CURCUMIN; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GARLIC; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; MAILLARD REACTION; MALE; OXIDATIVE STRESS;

EID: 84857720782     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912799424528     Document Type: Review

References (237)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-53.
2. Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004; 92: 1-21.
3. WHO. The World Health Organization 2007. Diabetes Programme: facts and figures [on line]. [Accessed 24 September 2008].
4. Maillard LC. Action of amino acids on sugars. Formation of melanoidins in a methodical way. Compte Rendu du roi 1912; 154: 66-8.
5. Fu MX, Wells-Knecht KJ, Blackledge JA et al. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676-83.
6. Ahmed N. Advanced glycation endproducts: role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.
7. Namiki M, Hayashi T. A new mechanism of the Maillard reaction involving sugar fragmentation and free radical formation. ACS Symp Series The Maillard reaction in foods and nutrition, American Chemical Society Symposium 1983; 215: 21-46.
8. Monnier VM. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003; 419: 1-15.
9. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
10. Sell DR, Nagaraj RH, Grandhee SK et al. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Rev 1991; 7: 239-51.
11. Nakamura K, Nakazawa Y, Ienaga K. Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose. Biochem Biophys Res Commun 1997; 232: 227-30.
12. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
13. Obayashi H, Nakano K, Shigeta H et al. Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. Biochem Biophys Res Commun 1996; 226: 37-41.
14. Dyer DG, Blackledge JA, Katz BM et al. The Maillard reaction in vivo. Z Ernahrungswiss 1991; 30: 29-45.
15. Chellan P, Nagaraj RH. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch Biochem Biophys 1999; 368: 98-104.
16. Farmar JG, Ulrich PC, Cerami A. Novel pyrroles from sulfiteinhibited Maillard reactions: insight into the mechanism of inhibition. J Org Chem 1988; 53: 2346-9.
17. Al-Abed Y, Bucala R. Structure of a synthetic glucose derived advanced glycation end product that is immunologically crossreactive with its naturally occurring counterparts. Bioconjug Chem 2000; 11: 39-45.
18. Shipanova IN, Glomb MA, Nagaraj RH. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch Biochem Biophys 1997; 344: 29-36.
19. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsiloncarboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-94.
20. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-(Carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997; 324: 565-70.
21. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM. Aging of proteins: immunological detection of a glucose-derived pyrrole formed during maillard reaction in vivo. J Biol Chem 1989; 264: 3758-64.
22. Paul RG, Avery NC, Slatter DA, Sims TJ, Bailey AJ. Isolation and characterization of advanced glycation end products derived from the in vitro reaction of ribose and collagen. Biochem J 1998; 330: 1241-8.
23. Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-91.
24. Nicholl ID, Stitt AW, Moore JE et al. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med 1998; 4: 594-601.
25. Cerami C, Founds H, Nicholl I et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997; 94: 13915-20.
26. Vitek MP, Bhattacharya K, Glendening JM et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 4766-70.
27. Ulrich P, Zhang X. Pharmacological reversal of advanced glycation end-product-mediated protein crosslinking. Diabetologia 1997; 40: S157-9.
28. Bach LA, Gallicchio MA, McRobert EA, Tikoo A, Cooper ME. Effects of advanced glycation end products on ezrin-dependent functions in LLC-PK1 proximal tubule cells. Ann NY Acad Sci 2005; 1043: 609-16.
29. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
30. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
31. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann NY Acad Sci 1997; 811: 115-27.
32. Meerwaldt R, Links T, Zeebregts C et al. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008; 7: 29.
33. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81: 583-7.
34. Tarsio JF, Wigness B, Rhode TD et al. Nonenzymatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus. Diabetes 1985; 34: 477-84.
35. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992; 267: 12404-7.
36. Mukhopadhyay S, Mukherjee TK. Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: a perspective. Biochim Biophys Acta 2005; 1745: 145-55.
37. Ayala A, Cutler RG. Comparison of 5-hydroxy-2-amino valeric acid with carbonyl group content as a marker of oxidized protein in human and mouse liver tissues. Free Radic Biol Med 1996; 21: 551-8.
38. Oak J, Nakagawa K, Miyazawa T. Synthetically prepared Amadori-glycated phosphatidylethanolamine can trigger lipid peroxidation via free radical reactions. FESS Lett 2000; 481: 26-30.
39. Seidel W, Pischetsrieder M. DNA-glycation leads to depurination by the loss of N2-carboxyethylguanine in vitro. Cell Mol Biol 1998; 44: 1165-70.
40. Pischetsrieder M, Seidel W, Munch G, Schinzel R. N(2)-(1- Carboxyethyl)deoxyguanosine, a nonenzymatic glycation adduct of DNA, induces single-strand breaks and increases mutation frequencies. Biochem Biophys Res Commun 1999; 264: 544-9.
41. DeGroot J, Verzijl N, Wenting-Van Wijk MJG et al. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum 2004; 50: 1207-15.
42. Li YM, Mitsuhashi T, Wojciechowicz D et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047-52.
43. Ohgami N, Nagai R, Ikemoto M et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 2002; 16: 56-59.
44. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
45. Neeper M, Schmidt AM, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
46. Chavakis T, Bierhaus A, Al-Fakhri N et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507-15.
47. Ramasamy R, Vannucci SJ, Yan SS et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16R-28R.
48. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
49. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.
50. Bierhaus A, Humpert PM, Morcos M et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-86.
51. Ma W, Lee SE, Guo J et al. RAGE ligand upregulation of vegf secretion in ARPE-19 cells. Invest Opthalmol Vis Sci 2007; 48: 1355-61.
52. Wautier MP, Chappey O, Corda S et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-94.
53. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care 2006; 29: 1420-32.
54. Yam JC, Kwok AK. Update on the treatment of diabetic retinopathy. Hong Kong Med J 2007; 13: 46-60.
55. Sato T, Iwaki M, Shimogaito N et al. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 2006; 6: 351-58.
56. Anitha B, Sampathkumar R, Balasubramanyam M, Rema M. Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. J Diabetes Complications 2008; 22: 261-6.
57. Stitt AW, Curtis TM. Advanced glycation and retinal pathology during diabetes. Pharmacol Rep 2005; 57: 156-68.
58. Linetsky M, Shipova E, Cheng R, Ortwerth BJ. Glycation by ascorbic acid oxidation products leads to the aggregation of lens proteins. Biochim Biophys Acta 2008; 1782: 22-34.
59. Coughlan MT, Cooper ME, Forbes JM. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes? Ann N Y Acad Sci 2005; 1043: 750-8.
60. Makino H, Shikata K, Hironaka K et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995; 48: 517-26.
61. Mitsuhashi T, Nakayama H, Itoh T et al. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes 1993; 42: 826-32.
62. Yoshida N, Okumura K-i, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005; 54: 345-50.
63. Weiss MF, Erhard P, Kader-Attia FA et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57: 2571-85.
64. Shimoike T, Inoguchi T, Umeda F et al. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000; 49: 1030-35.
65. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-4.
66. Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann NY Acad Sci 2005; 1043: 598-604.
67. Ryle C, Leow CK, Donaghy M. Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus. Muscle Nerve 1997; 20: 577-84.
68. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci USA 1981; 78: 5190-92.
69. Williams SK, Howarth NL, Devenny JJ, Bitensky MW. Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc Natl Acad Sci USA 1982; 79: 6546-50.
70. Amore A, Cirina P, Mitola S et al. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int 1997; 51: 27-35.
71. Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 2007; 9: 767-80.
72. King KD, Jones JD, Warthen J. Microvascular and macrovascular complications of diabetes mellitus. Am J Pharm Educ 2005; 69: 1-10.
73. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Athero Rep 2000; 2: 430-36.
74. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-52.
75. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46: 284-7.
76. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 255-64.
77. Matsumoto K, Sano H, Nagai R et al. Endocytic uptake of advanced glycation endproducts by mouse liver sinusoidal endothelial cells is mediated by a receptor distinct from the class A scavenger receptor. Biochem J 2000; 352: 233-40.
78. Thornalley PJ. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 2003; 31: 1341-2.
79. Gerhardinger C, Marion MS, Rovner A, Glomb M, Monnier VM. Novel degradation pathway of glycated amino acids into free fructosamine by a Pseudomonas sp. soil strain extract. J Biol Chem 1995; 270: 218-24.
80. Monnier VM, Wu X. Enzymatic deglycation with Amadoriase enzymes from Aspergillus sp. as a potential strategy against the complications of diabetes and aging. Biochem Soc Trans 2003; 31: 1349-53.
81. Wu X, Monnier VM. Enzymatic deglycation of proteins. Arch Biochem Biophys 2003; 419: 16-24.
82. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000; 26: 163-76.
83. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post- Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999; 257: 251-8.
84. Blakytny R, Harding JJ. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res 1992; 54: 509-18.
85. Mendez JD, Leal LI. Inhibition of in vitro pyrraline formation by L-arginine and polyamines. Biomed Pharmacother 2004; 58: 598-604.
86. Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS Lett 1995; 371: 81-5.
87. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005; 6: 453-74.
88. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 63-79.
89. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxic 2003; 17: 24-38.
90. Duraisamy Y, Gaffney J, Slevin M, Smith CA, Williamson K, Ahmed N. Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine. Mol Cell Biochem 2003; 246: 143-53.
91. Selvaraj N, Bobby Z, Sathiyapriya V. Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. Clin Chim Acta 2006; 366: 190-95.
92. Ramakrishnan S, Sulochana KN, Punitham R. Two new functions of inositol in the eye lens: antioxidation and antiglycation and possible mechanisms. Ind J Biochem Biophys 1999; 36: 129-133.
93. Takagi Y, Kashiwagi A, Tanaka Y, Asahina T, Kikkawa R, Shigeta Y. Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Complications 1995; 9: 87-91.
94. Jairajpuri DS, Fatima S, Saleemuddin M. Immunoglobulin glycation with fructose: A comparative study. Clin Chim Acta 2007; 378: 86-92.
95. Jakus V, Hrnciarova M, Carsky J, Krahulec B, Rietbrock N. Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity. Life Sci 1999; 65: 1991-3.
96. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276: 48967-72.
97. Figarola JL, Scott S, Loera S, Xi B, Synold T, Rahbar S. Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocininduced diabetic rats. Ann NY Acad Sci USA 2005; 1043: 767-76.
98. Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the alphaoxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 2000; 60: 55-65.
99. Kiho T, Kato M, Usui S, Hirano K. Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Clin Chim Acta 2005; 358: 139-45.
100. Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 2003; 278: 42012-9.
101. Miyata T, Ishikawa S, Asahi K et al. 2-Isopropylidenehydrazono-4- oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. Fed Eur Biochem Soc Lett 1999; 445: 202-6.
102. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003; 419: 89-96.
103. Cooper ME, Thallas V, Forbes J et al. The cross-link breaker, Nphenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-4.
104. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrin Metab 2000; 11: 368-75.
105. Bucciarelli LG, Wendt T, Rong L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59: 1117-28.
106. Goova MT, Li J, Kislinger T et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513-25.
107. Sakurai S, Yamamoto Y, Tamei H et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006; 73: 158-65.
108. Rahbar S, Natarajan R, Yerneni K et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65-77.
109. Demiot C, Tartas M, Fromy B et al. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes 2006; 55: 1478-83.
110. Shoda H, Miyata S, Liu BF et al. Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 1997; 138: 1886-92.
111. Okamoto T, Yamagishi S, Inagaki Y et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30.
112. Okamoto T, Yamagishi S, Inagaki Y et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun 2002; 297: 419-24.
113. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Current Science 2004; 86: 789-94.
114. Grover JK, Yadav S, Vats V. Medicinal plants of India with antidiabetic potential. J Ethnopharmacol 2002; 81: 81-100.
115. Yokozawa T, Nakagawa T. Inhibitory effects of Luobuma tea and its components against glucose-mediated protein damage. Food Chem Toxicol 2004; 42: 975-81.
116. Peng X, Zheng Z, Cheng K-W et al. Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts. Food Chem 2008; 106: 475-81.
117. Sajithlal GB, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 1998; 56: 1607-14.
118. Kiho T, Usui S, Hirano K, Aizawa K, Inakuma T. Tomato paste fraction inhibiting the formation of advanced glycation endproducts. Biosci Biotech Biochem 2004; 68: 200-5.
119. Rudnicki M, de Oliveira MR, Veiga Pereira Td, Reginatto FH, Dal-Pizzol F, Fonseca Moreira JC. Antioxidant and antiglycation properties of Passiflora alata and Passiflora edulis extracts. Food Chem 2007; 100: 719-24.
120. Hsieh C-L, Lin Y-C, Ko W-S et al. Inhibitory effect of some selected nutraceutic herbs on LDL glycation induced by glucose and glyoxal. J Ethnopharmacol 2005; 102: 357-63.
121. Rout S, Banerjee R. Free radical scavenging, anti-glycation and tyrosinase inhibition properties of a polysaccharide fraction isolated from the rind from Punica granatum. Bioresour Technol 2007; 98: 3159-63.
122. Ardestani A, Yazdanparast R. Cyperus rotundus suppresses AGE formation and protein oxidation in a model of fructose-mediated protein glycoxidation. Int J Biol Macromol 2007; 41: 572-8.
123. Ahmad MS, Pischetsrieder M, Ahmed N. Aged garlic extract and S-allyl cysteine prevent formation of advanced glycation endproducts. Eur J Pharmacol 2007; 561: 32-8.
124. Kim HY, Kim K. Protein glycation inhibitory and antioxidative activities of some plant extracts in vitro. J Agr Food Chem 2003; 51: 1586-91.
125. Babu PVA, Sabitha KE, Shyamaladevi CS. Effect of green tea extract on advanced glycation and cross-linking of tail tendon collagen in streptozotocin induced diabetic rats. Food Chem Toxicol 2008; 46: 280-5.
126. Chaiyasut C, and Chansakaow S. Inhibitory effects of some thai plant extracts on AAPH-induced protein oxidation and protein glycation. Naresuan University Journal 2007; 15: 35-41.
127. Yamaguchi F, Ariga T, Yoshimura Y, Nakazawa H. Antioxidative and anti-glycation activity of garcinol from Garcinia indica fruit rind. J Agr Food Chem 2000; 48: 180-5.
128. Jedsadayanmata A. In vitro antiglycation activity of arbutin. Naresuan University Journal 2005; 13: 35-41.
129. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595: 1-75.
130. Srinivasan KR. A chromatographic study of the curcuminoids in Curcuma longa, L. J Pharm Pharmacol 1953; 5: 448-57.
131. Araujo CC, Leon LL. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 2001; 96: 723-8.
132. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 1-7.
133. Naidu KA, Thippeswamy NB. Inhibition of human low density lipoprotein oxidation by active principles from spices. Mol Cell Biochem 2002; 229: 19-23.
134. Babu PS, Srinivasan K. Hypolipidemic action of curcumin, the active principle of turmeric in streptozotocin induced diabetic rats. Mol Cell Biochem 1997; 166: 169-75.
135. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of curcumin. Thromb Res 1985; 40: 413-7.
136. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 1998; 124: 425-7.
137. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H. Antihepatotoxic principles of Curcuma longa Rhizomes1. Planta Med 1983; 49: 185-7.
138. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agr Food Chem 1999; 47: 4297-300.
139. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71: 632-4.
140. Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem 1993; 1: 415-22.
141. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol 1998; 111: 656-61.
142. Ravindran J, Prasad S, Aggarwal B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 2009; 11: 495-510.
143. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002; 23: 143-50.
144. Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi BV, Khar A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett 1999; 456: 311-4.
145. Nishiyama T, Mae T, Kishida H et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agr Food Chem 2005; 53: 959-63.
146. Suryanarayana P, Saraswat M, Mrudula T et al. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophth Vis Sci 2005; 46: 2092-9.
147. Tharakan B, Hunter FA, Smythe WR, Childs EW. Curcumin inhibits reactive oxygen species formation and vascular hyperpermeability following haemorrhagic shock. Clin Exp Pharmacol Physiol 2010; 37: 939-44.
148. Sidhu GS, Mani H, Gaddipati JP et al. Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen 1999; 7: 362-74.
149. Seo KI, Choi MS, Jung UJ et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008; 52: 995-1004.
150. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acidand phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20: 445-51.
151. Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13- acetate in NIH 3T3 cells. Carcinogenesis 1993; 14: 857-61.
152. Hong R-L, Spohn WH, Hung M-C. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 1999; 5: 1884-91.
153. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 2001; 38: 179-85.
154. Kellett GL, Brot-Laroche E. Apical GLUT2: a major pathway of intestinal sugar absorption. Diabetes 2005; 54: 3056-62.
155. Sivabalan S, Anuradha CV. A comparative study on the antioxidant and glucose-lowering effects of curcumin and bisdemethoxycurcumin analog through in vitro assays. Int J Pharmacol 2010; 6: 664-9.
156. Jain SK, Rains J, Jones K. Effect of curcumin on protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels. Free Radic Biol Med 2006; 41: 92-6.
157. Wright JS. Predicting the antioxidant activity of curcumin and curcuminoids. J Mol Struct 2002; 591: 207-17.
158. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-5.
159. Ghoneim AI, Abdel-Naim AB, Khalifa AE, El-Denshary ES. Protective effects of curcumin against ischaemia/reperfusion insult in rat forebrain. Pharmacol Res 2002; 46: 273-9.
160. Ishihara M, Sakagami H. Re-evaluation of cytotoxicity and iron chelation activity of three beta-diketones by semiempirical molecular orbital method. In Vivo 2005; 19: 119-23.
161. Anand P, Thomas SG, Kunnumakkara AB et al. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. Biochem Pharmacol 2008; 76: 1590-1611.
162. Dhillon N, Aggarwal BB, Newman RA et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.
163. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. Indian J Exp Biol 1980; 18: 73-5.
164. Lao CD, Ruffin MTt, Normolle D et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.
165. Cabrera C, Gimenez R, Lopez MC. Determination of tea components with antioxidant activity. J Agr Food Chem 2003; 51: 4427-35.
166. Sabu MC, Smitha K, Kuttan R. Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol 2002; 83: 109-16.
167. Cabrera C, Artacho R, Gimenez R. Beneficial effects of green tea-- a review. J Am Coll Nutr 2006; 25: 79-99.
168. Zuo Y, Chen H, Deng Y. Simultaneous determination of catechins, caffeine and gallic acids in green, oolong, black and pu-erh teas using HPLC with a photodiode array detector. Talanta 2002; 57: 307-16.
169. McKay DL, Blumberg JB. The role of tea in human health: an update. J Am Coll Nutr 2002; 21: 1-13.
170. Singh R, Akhtar N, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. Life Sci 2010; 86: 907-18.
171. Xie M, von Bohlen A, Klockenkämper R, Jian X, Günther K. Multielement analysis of Chinese tea (Camellia sinensis) by totalreflection X-ray fluorescence. Zeitschrift für Lebensmitteluntersuchung und -Forschung A 1998; 207: 31-8.
172. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003; 133: 3275S-84S.
173. Cheng KW, Wong CC, Chao J et al. Inhibition of mutagenic PhIP formation by epigallocatechin gallate via scavenging of phenylacetaldehyde. Mol Nutr Food Res 2009; 53: 716-25.
174. Kavanagh KT, Hafer LJ, Kim DW et al. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem 2001; 82: 387-98.
175. Xiao X, Yang ZQ, Shi LQ, Liu J, Chen W. Antiviral effect of epigallocatechin gallate (EGCG) on influenza A virus. Zhongguo Zhong Yao Za Zhi 2008; 33: 2678-82.
176. Dona M, Dell'Aica I, Calabrese F et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 2003; 170: 4335-41.
177. Moon HS, Lee HG, Choi YJ, Kim TG, Cho CS. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity. Chem Biol Interact 2007; 167: 85-98.
178. Smith A, Giunta B, Bickford PC et al. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm 2010; 389: 207-12.
179. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 1995; 310: 693-6.
180. Kuriyama S, Hozawa A, Ohmori K et al. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr 2006; 83: 355-61.
181. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000; 13: 49-54.
182. Tsuneki H, Ishizuka M, Terasawa M et al. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol 2004; 4: 18.
183. Anderson RA, Polansky MM. Tea enhances insulin activity. J Agric Food Chem 2002; 50: 7182-6.
184. Gomes A, Vedasiromoni JR, Das M, Sharma RM, Ganguly DK. Anti-hyperglycemic effect of black tea (Camellia sinensis) in rat. J Ethnopharmacol 1995; 45: 223-6.
185. Wu LY, Juan CC, Hwang LS et al. Green tea supplementation ameliorates insulin resistance and increases glucose transporter IV content in a fructose-fed rat model. Eur J Nutr 2004; 43: 116-24.
186. Waltner-Law ME, Wang XL, Law BK et al. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem 2002; 277: 34933-40.
187. Iso H, Date C, Wakai K, Fukui M, Tamakoshi A. The relationship between green tea and total caffeine intake and risk for selfreported type 2 diabetes among Japanese adults. Ann Intern Med 2006; 144: 554-62.
188. Fukino Y, Shimbo M, Aoki N, Okubo T, Iso H. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutr Sci Vitaminol (Tokyo) 2005; 51: 335-42.
189. Hosoda K, Wang MF, Liao ML et al. Antihyperglycemic effect of oolong tea in type 2 diabetes. Diabetes Care 2003; 26: 1714-8.
190. Fukino Y, Ikeda A, Maruyama K et al. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr 2008; 62: 953-60.
191. Ryu OH, Lee J, Lee KW et al. Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. Diabetes Res Clin Pract 2006; 71: 356-8.
192. Thielecke F, Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome - a review. Phytochemistry 2009; 70: 11-24.
193. Babu PV, Sabitha KE, Shyamaladevi CS. Therapeutic effect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. Chem Bio Interact 2006; 162: 114-20.
194. Wu LY, Juan CC, Ho LT, Hsu YP, Hwang LS. Effect of green tea supplementation on insulin sensitivity in Sprague-Dawley rats. J Agric Food Chem 2004; 52: 643-8.
195. Kobayashi Y, Suzuki M, Satsu H et al. Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J Agric Food Chem 2000; 48: 5618-23.
196. Rizvi SI, Zaid MA, Anis R, Mishra N. Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes. Clin Exp Pharmacol Physiol 2005; 32: 70-5.
197. Vinson JA, Zhang J. Black and green teas equally inhibit diabetic cataracts in a streptozotocin-induced rat model of diabetes. J Agric Food Chem 2005; 53: 3710-3.
198. Ho S-C, Wu S-P, Lin S-M, Tang Y-L. Comparison of antiglycation capacities of several herbal infusions with that of green tea. Food Chem 2010; 122: 768-74.
199. Rasheed Z, Anbazhagan AN, Akhtar N et al. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end productinduced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009; 11: R71.
200. Wu C-H, Yeh C-T, Yen G-C. Epigallocatechin gallate (EGCG) binds to low-density lipoproteins (LDL) and protects them from oxidation and glycation under high-glucose conditions mimicking diabetes. Food Chem 2010; 121: 639-44.
201. Dearlove RP, Greenspan P, Hartle DK, Swanson RB, Hargrove JL. Inhibition of protein glycation by extracts of culinary herbs and spices. J Med Food 2008; 11: 275-81.
202. Kashima M. Effects of catechins on superoxide and hydroxyl radical. Chem Pharm Bull (Tokyo) 1999; 47: 279-83.
203. Morihara N, Nishihama T, Ushijima M, Ide N, Takeda H, Hayama M. Garlic as an anti-fatigue agent. Mol Nutr Food Res 2007; 51: 1329-34.
204. Lawson LD. The composition and chemistry of garlic cloves and processed garlic. USA: Williams and Wilkins Press, 1996.
205. Fleischauer AT, Arab L. Garlic and cancer: a critical review of the epidemiologic literature. J Nutr 2001; 131: 1032S-40S.
206. Matsuura H. Saponins in garlic as modifiers of the risk of cardiovascular disease. J Nutr 2001; 131: 1000S-1005S.
207. Kyo E, Uda N, Kasuga S, Itakura Y. Immunomodulatory effects of aged garlic extract. J Nutr 2001; 131: 1075S-9S.
208. Wei Z, Lau BHS. Garlic inhibits free radical generation and augments antioxidant enzyme activity in vascular endothelial cells. Nutr Res 1998; 18: 61-70.
209. Rahman K. Garlic and aging: new insights into an old remedy. Age Res Rev 2003; 2: 39-56.
210. Chauhan NB. Multiplicity of garlic health effects and Alzheimer's disease. J Nutr Health Aging 2005; 9: 421-32.
211. Sheikh N, Safari MRM, Mani KK, Araghchian M, Zeraati F. Study on the effect of gatlic on the in vitro albumin glycation reaction. Acta Medica Iranica 2004; 42.
212. Dillon SA, Burmi RS, Lowe GM, Billington D, Rahman K. Antioxidant properties of aged garlic extract: an in vitro study incorporating human low density lipoprotein. Life Sci 2003; 72: 1583-94.
213. Narayana KR, Reddy MS, Chaluvadi MR, Krishna DR. Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Ind J Pharmacol 2001; 33: 2-16.
214. Bors W, Heller W, Michel C, Saran M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Meth Enzymol 1990; 186: 343-55.
215. Brasseur T. Anti-inflammatory properties of flavonoids. Journal de pharmacie de Belgique 1989; 44: 235-41.
216. Auger C, Teissedre P-L, Gerain P et al. Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect hypercholesterolemic hamsters against aortic fatty streak accumulation. J Agr Food Chem 2005; 53: 2015-21.
217. Yokozawa T, Kashiwada Y, Hattori M, Chung HY. Study on the components of luobuma with peroxynitrite-scavenging activity. Biol Pharm Bull 2002; 25: 748-52.
218. Kim D, Yokozawa T, Hattori M, Kadota S, Namba T. Luobuma leaf inhibits oxidation of low density lipoprotein in cholesterol-fed rats. J Trad Med 1998; 15: 40-4.
219. Yokozawa T, Dong E, Kashiwagi H et al. In vitro and in vivo studies on anti-lipid peroxidation effect of extract from Luobuma leaves. Nat Med 1997; 51: 325-30.
220. Hatano T, Edamatsu R, Hiramatsu M et al. Effects of the interaction of tannins with co-existing substances. VI. Effects of tannins and related polyphenols on superoxide anion radical, and on 1,1-diphenyl-2-picrylhydrazyl radical. Chem Pharm Bull 1989; 37: 2016-21.
221. Yokozawa T, Chen CP, Dong E et al. Study on the inhibitory effect of tannins and flavonoids against the 1,1-diphenyl-2 picrylhydrazyl radical. Biochem Pharmacol 1998; 56: 213-22.
222. DiMascio P, Kaiser S, Sies S. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989; 274: 532-8.
223. Rao AV. Lycopene, tomatoes, and the prevention of coronary heart disease. Exp Biol Med (Maywood) 2002; 227: 908-13.
224. Kucuk O, Sarkar FH, Sakr W et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001; 10: 861-8.
225. Stewart AJ, Bozonnet S, Mullen W et al. Occurrence of flavonols in tomatoes and tomato-based products. J Agric Food Chem 2000; 48: 2663-9.
226. Rao AV, Agarwal S. Role of lycopene as antioxidant carotenoid in the prevention of chronic diseases: a review. Nutr Res 1999; 19: 305-23.
227. Sahin N, Orhan C, Tuzcu M, Sahin K, Kucuk O. The effects of tomato powder supplementation on performance and lipid peroxidation in quail. Poult Sci 2008; 87: 276-83.
228. Agarwal S, Rao AV. Tomato lycopene and its role in human health and chronic diseases. CMAJ 2000; 163: 739-44.
229. Beecher GR. Nutrient content of tomatoes and tomato products. Proc Soc Exp Biol Med 1998; 218: 98-100.
230. Giovannucci E, Ascherio A, Rimm EB et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767-76.
231. Narisawa T, Fukaura Y, Hasebe M et al. Prevention of Nmethylnitrosourea induced colon carcinogenesis in F344 rats by lycopene and tomato juice rich in lycopene. Jpn J Cancer Res 1998; 89: 1003-8.
232. Willcox JK, Catignani GL, Lazarus S. Tomatoes and cardiovascular health. Crit Rev Food Sci Nutr 2003; 43: 1-18.
233. Lazarus SA, Garg ML. Tomato extract inhibits human platelet aggregation in vitro without increasing basal cAMP levels. Int J Food Sci Nutr 2004; 55: 249-56.
234. Yamamoto J, Taka T, Yamada K et al. Tomatoes have natural antithrombotic effects. Br J Nutr 2003; 90: 1031-8.
235. Upritchard JE, Sutherland WH, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 2000; 23: 733-8.
236. Agarwal S, Rao AV. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. Lipids 1998; 33: 981-4.
237. Porrini M, Riso P. Lymphocyte lycopene concentration and DNA protection from oxidative damage is increased in women after a short period of tomato consumption. J Nutr 2000; 130: 189-92.